1. Introduction

The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with a novel coronavirus identified in Wuhan, China (See: Surveillance case definitions for human infection with novel coronavirus, Interim guidance).

Various existing WHO documents have been adapted for use in the drafting of this document, including WHO laboratory guidance for MERS-CoV (1-11). As information about the etiology, clinical manifestations and transmission of disease in the cluster of respiratory disease patients identified in Wuhan is evolving, WHO continues to monitor developments and will revise these recommendations as necessary.

The etiologic agent responsible for the cluster of pneumonia cases in Wuhan has been identified as a novel beta-coronavirus, (in the same family as SARS-CoV and MERS-CoV) via next generation sequencing (NGS) from cultured virus or directly from samples received from several pneumonia patients. Electron microscopy revealed a virus with a characteristic crown morphology: a coronavirus. Working directly from sequence information, the team developed a series of genetic amplification (PCR) assays used by laboratories associated with the China CDC to detect several dozen cases as of today.

Full genome sequence data from the viruses have been shared officially with WHO and on the GISAID platform (https://www.gisaid.org/) and can inform the development of specific diagnostic tests for this emergent coronavirus. It is expected that validated PCR tests will become available soon. Until that time, the goals of diagnostic testing are to detect conventional causes of pneumonia early, to support disease control activities, and to work with reference laboratories that can perform pan coronavirus detection and directed sequencing.

2. Suspected case definition

For case definition see: WHO Surveillance case definitions for human infection with novel coronavirus.

3. Specimen collection and shipment

Rapid collection and testing of appropriate specimens from suspected cases is a priority and should be guided by a laboratory expert. As extensive testing is still needed to confirm the 2019-nCoV and the role of mixed infection has not been verified, multiple tests may need to be performed and sampling sufficient clinical material is recommended. Local guidelines should be followed regarding patient or guardian’s informed consent for specimen collection, testing and potentially future research.

Assure SOPs are available, and the appropriate staff is trained and available for appropriate collection, specimen storage, packaging and transport. There is still limited information on the risk posed by the reported coronavirus found in Wuhan, but it would appear samples prepared for molecular testing could be handled as would samples of suspected human influenza (2, 7-9). Attempts to culture the virus may require heightened biosafety control measures.

Samples to be collected (see Table 1 for details on sample collection and storage):

1. Respiratory material* (nasopharyngeal and oropharyngeal swab in ambulatory patients and sputum (if produced) and/or endotracheal aspirate or bronchoalveolar lavage in patients with more severe respiratory disease)

2. Serum for serological testing, acute sample and convalescent sample (this is additional to respiratory materials and can support the identification of the true agent, once serologic assay is available)

*Modifiable with information on whether upper or lower respiratory material is better for coronavirus detection.

A single negative test result, particularly if this is from an upper respiratory tract specimen, does not exclude infection. Repeat sampling and testing, lower respiratory specimen is strongly recommended in severe or progressive disease. A positive alternate pathogen does not necessarily rule out either, as little is yet known about the role of coinfections.

Reference 2, 3, 7
## Table 1. Specimens to be collected from symptomatic patients
Guidance on specimen collection (adapted from reference 5)

<table>
<thead>
<tr>
<th>Specimen type</th>
<th>Collection materials</th>
<th>Transport to laboratory</th>
<th>Storage till testing</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasopharyngeal and oropharyngeal swab</td>
<td>Dacron or polyester flocked swabs*</td>
<td>4 °C</td>
<td>≤5 days: 4 °C</td>
<td>The nasopharyngeal and oropharyngeal swabs should be placed in the same tube to increase the viral load.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;5 days: -70 °C</td>
<td></td>
</tr>
<tr>
<td>Bronchoalveolar lavage</td>
<td>sterile container *</td>
<td>4 °C</td>
<td>≤48 hours: 4 °C</td>
<td>There may be some dilution of pathogen, but still a worthwhile specimen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;48 hours: -70 °C</td>
<td></td>
</tr>
<tr>
<td>(Endo)tracheal aspirate, nasopharyngeal aspirate</td>
<td>sterile container *</td>
<td>4 °C</td>
<td>≤48 hours: 4 °C</td>
<td></td>
</tr>
<tr>
<td>or nasal wash</td>
<td></td>
<td></td>
<td>&gt;48 hours: -70 °C</td>
<td></td>
</tr>
<tr>
<td>Sputum</td>
<td>sterile container</td>
<td>4 °C</td>
<td>≤48 hours: 4 °C</td>
<td>Ensure the material is from the lower respiratory tract</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;48 hours: -70 °C</td>
<td></td>
</tr>
<tr>
<td>Tissue from biopsy or autopsy including from lung</td>
<td>sterile container with saline</td>
<td>4 °C</td>
<td>≤24 hours: 4 °C</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;24 hours: -70 °C</td>
<td></td>
</tr>
<tr>
<td>Serum (2 samples acute and convalescent possibly</td>
<td>Serum separator tubes (adults: collect 3-5 ml whole blood)</td>
<td>4 °C</td>
<td>≤5 days: 4 °C</td>
<td>Collect paired samples: • acute – first week of illness • convalescent – 2 to 3 weeks later</td>
</tr>
<tr>
<td>2-4 weeks after acute phase)</td>
<td></td>
<td></td>
<td>&gt;5 days: -70 °C</td>
<td></td>
</tr>
<tr>
<td>Whole blood</td>
<td>collection tube</td>
<td>4 °C</td>
<td>≤5 days: 4 °C</td>
<td>For antigen detection particularly in the first week of illness</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;5 days: -70 °C</td>
<td></td>
</tr>
<tr>
<td>Urine</td>
<td>urine collection container</td>
<td>4 °C</td>
<td>≤5 days: 4 °C</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;5 days: -70 °C</td>
<td></td>
</tr>
</tbody>
</table>

*For transport of samples for viral detection, use VTM (viral transport medium) containing antifungal and antibiotic supplements. For bacterial or fungal culture, transport dry or in a very small amount of sterile water. Avoid repeated freezing and thawing of specimens.

Aside from specific collection materials indicated in the table also assure other materials and equipment are available: e.g. transport containers and specimen collection bags and packaging, coolers and cold packs or dry ice, sterile blood-drawing equipment (e.g. needles, syringes and tubes), labels and permanent markers, PPE, materials for decontamination of surfaces.

### Safety procedures during sample collection and transport

All specimens collected for laboratory investigations should be regarded as potentially infectious, and HCWs who collect, or transport clinical specimens should adhere rigorously to infection prevention and control guidelines and national or international regulations for the transport of dangerous goods (infectious substances) to minimize the possibility of exposure to pathogens (14). Implement the appropriate infection prevention and control precautions, guidance on IPC for the 2019-nCoV has been drafted (11).

### Assure good communication with the laboratory and provide needed information

To assure proper and fast processing of samples and to assure adequate biosafety measures in the laboratory, communication and information sharing is essential. Be sure you have alerted the laboratory of the urgency and situation before sending the sample. Also assure that specimens are correctly labelled, and diagnostic request forms are filled out properly and clinical information is provided (see box: information to be recorded).

**Information to be recorded:**
- Patient information – name, date of birth, sex and residential address, unique identification number, other useful information (e.g. patient hospital number, surveillance identification number, name of hospital, hospital address, room number, physicians’ name and contact information, name and address for report recipient),
- Date and time of sample collection,
- Anatomical site and location of specimen collection,
- Tests requested,
- Clinical symptoms and relevant patient history (including vaccination and antimicrobial therapies received, epidemiological information, risk factors).
4. Effective usage of Global Laboratory Networking

Timely and accurate laboratory testing of specimens from cases under investigation is an essential part of the management of emerging infections. All countries should have access to reliable testing, either nationally or internationally, in laboratories willing to perform primary detection or confirmatory testing, and novel pathogen detection. WHO is currently working closely with collaborating centres and experts to assure diagnostics will be developed and validated promptly. WHO can assist Member States to access testing internationally should the need arise.

5. Testing of 2019-nCoV in reference laboratories

2019-nCoV testing for patients that meet the suspected case definition

Patients that meet the case definition for suspected 2019-nCoV should be screened for the virus with PCR (details below). If case management requires, screen also for other common causes of respiratory illness according to local guidelines (1,5,7). As coinfections can occur, all patients that meet the case definition should be tested for 2019-nCoV regardless of whether a conventional respiratory pathogen is found. If testing does not occur in an expert/reference laboratory it is encouraged to send the sample for confirmation to a regional, national or international reference laboratory with pan-coronavirus or specific 2019-nCoV detection capacity. WHO can assist Member States to identify laboratories able to provide this support.

Nucleic acid amplification tests for 2019-nCoV

As sequence information from the 2019-nCoV has recently been made available, PCR assays can be designed to detect these sequences. PCR assay design optimization can be a complicated process, and a useful option is to contact the experienced laboratories publicizing their assays and request access to their assay chemistries.

Laboratories may desire to use a pan-coronavirus assay for amplification followed by sequencing of amplicons from non-conserved regions for characterization and confirmation. The importance of the need for confirmation of results of testing with pan-coronavirus primers is underscored by the fact that four human coronaviruses (HCoVs) are endemic globally: HCoV-229E, HCoV-NL63, HCoV-HKU1 as well as HCoV-OC43. The latter two are betacoronaviruses. Two other betacoronaviruses that cause zoonotic infection in humans are MERS-CoV, acquired by contact with dromedary camels and SARS arising from civets and cave-dwelling horseshoe bats.

Alternatively, amplification and detection of 2019-nCoV specific sequences can be diagnostic without the necessity for further sequencing. In the case of surprising findings or for less-experienced laboratories, external assistance should
be sought from a reference laboratory that can deploy additional or confirmatory assays.

Once specific NAAT assays are developed and validated, confirmation of cases of the novel virus infection will be based on specific detection of unique sequences of viral nucleic acid by reverse-transcriptase polymerase chain reaction (RT-PCR). Alternative NAAT techniques with advantages of greater speed or simplicity of use may also become available.

**Serological testing**

Serological testing may be useful to confirm immunologic response to a pathogen from a specific viral group, e.g. coronavirus. Best results from serologic testing requires the collection of paired serum samples (in the acute and convalescent phase) from cases under investigation.

**Sequencing in outbreaks**

Sequence data can provide valuable information for understanding the origin of a virus and how it is spreading. WHO has published a Draft code of conduct for the handling of Genetic Sequence Data related to outbreaks (see https://www.who.int/blueprint/what/norms-standards/GSDDraftCodeConduct_forpublicconsultation-v1.pdf?ua=1). For situations where data providers seek retention of ownership of their data, models with data access agreements (such as GISAID) have been used to facilitate rapid sharing of genetic sequence data. Laboratories are encouraged to share sequence data with WHO and the scientific community to assist in the rapid development and distribution of diagnostic assays in at risk countries. The uploading and public access to sequence data should occur prior to journal publication. Medical journals should ensure that their policies actively support pre-publication sharing of pathogen genetic sequence data together with appropriate acknowledgement. WHO can assist Member States to identify laboratories able to provide support and advise them on the management of sequence data related to an outbreak.

<table>
<thead>
<tr>
<th>Test</th>
<th>Type of sample</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>In laboratories that have validated broad coronavirus RT-PCR assays it is advised to check the primers against the published 2019-nCoV sequence and check if primers are overlapping and have the capacity to detect the 2019-nCoV. On a positive results sequencing should be performed to determine the precise virus detected (e.g. on an amplicon of a non-conserved region).</td>
<td>Respiratory sample</td>
<td>Collect on presentation. Done by an expert laboratory.</td>
</tr>
<tr>
<td>NAAT for 2019-nCoV when it becomes available (assays currently under validation)</td>
<td>Respiratory sample</td>
<td>Collect on presentation. Done by an expert laboratory until validation has been finalized.</td>
</tr>
<tr>
<td>Whole genome sequencing</td>
<td>Respiratory sample</td>
<td>Collect on presentation. Done by an expert laboratory.</td>
</tr>
<tr>
<td>Serology, broad corona virus serology on paired samples if available.</td>
<td>Serum</td>
<td>Paired samples necessary for confirmation, the first sample collected in week 1 of illness and the second collected 3-4 weeks later. If a single serum sample can be collected, collect at least 3 weeks after onset of symptoms. Done by expert laboratory until more information on performance of available assays.</td>
</tr>
</tbody>
</table>

---

**Specify for biosafety practices in the laboratory**

Ensure that health laboratories adhere to appropriate biosafety practices. Any testing on clinical specimens from patient meeting the case definition should be performed in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. National guidelines on the laboratory biosafety should be followed in all circumstances. General information on laboratory biosafety guidelines, see the WHO Laboratory Biosafety Manual, 3rd edition (8). There is still limited information on the risk posed by the reported coronavirus found in Wuhan, but it would appear samples prepared for molecular testing could be handled as would samples of suspected human influenza (2, 7-9).

It is recommended that all manipulations in laboratory settings of samples originating from suspected or confirmed cases of novel coronaviruses can be conducted according to WHO recommendations available at: https://www.who.int/csr/disease/coronavirus_infections/Biosafety_InterimRecommendations_NovelCoronavirus2012_31Oct12.pdf?ua=1 Information on biosafety for SARS, a Betacoronavirus that can cause severe respiratory disease can be consulted at https://www.who.int/csr/sars/biosafety2003_04_25/en/ and other guidance.
6. Reporting of cases and test results

Laboratories should follow national reporting requirements, but in general, suspected cases should be reported to relevant public health authorities as soon as the laboratory receives a specimen, even before any testing is performed. All test results, whether positive or negative, should likewise be immediately reported to national authorities. If the infection becomes widespread, laboratories should notify public health authorities immediately of each new confirmed case or positive screening test if there will be a delay in confirmatory testing. Laboratories should also periodically report the number of negative test results to public health.

States Parties to the IHR are reminded of their obligations to share with WHO relevant public health information for events for which they notified WHO, using the decision instrument in Annex 1 of the IHR (2005) (18).

Detection of a possible human case of emerging pathogen causing severe acute respiratory disease should immediately be notified to local, subnational and national public health authorities. This will allow these authorities to make immediate decisions about launching the investigation and the extent of response measures. Detection of such a case should be used to trigger notification of traditional and non-traditional health providers, hospitals and outpatient. Facilities, and community leaders in the area where the case patients lived or travelled, as part of active case-finding efforts. In line with the International Health Regulations (IHR) (2005), the national health authority must notify WHO within 24 hours of all events that may constitute a public health emergency of international concern according to defined criteria. The IHR decision instrument should be used to determine whether an event is to be notified to WHO. Further guidance on the use of the IHR decision instrument, including examples of its application, is available. The national animal health authority must notify OIE of certain animal diseases detected on its territory. OIE focal points should be contacted for further details.

7. Acknowledgements

The following people contributed to the drafting of this guidance document: Maria Zambon, Public Health England, UK; Christian Drosten, Charité - Universitätsmedizin Berlin, Germany; Marion Koopmans, Erasmus MC, Rotterdam, The Netherlands; David Alland, Rutgers Medical School, USA; George Gao, Chinese CDC, China.

WHO Health Emergency Programme: Katelijn Vandemaele, Magdi Samaan, Christian Fuster, Wenqing Zhang, Céline Barnadas, Lisa Stevens, Chris Oxenford, Sebastian Cognat, Kazunobu Kojima, Carmen Dolea, Maria Van Kerkhove, Mark D Perkins and Karin von Eije. WHO Science Division: Vasee Moorthy

8. References


3) Investigation of cases of human infection with Middle East respiratory syndrome coronavirus (MERS-CoV), interim guidance, World Health Organization, updated June 2018 WHO/ERS/SUR/15.2 Revision 1 (https://apps.who.int/iris/bitstream/handle/10665/178252/WHO_MERS_SUR_15.2_eng.pdf;sequence=1)

4) Surveillance for human infection with Middle East respiratory syndrome coronavirus (MERS-CoV), interim guidance, Updated June 2018, WHO/MERS/SUR/15.1 Revision 1 (https://apps.who.int/iris/bitstream/handle/10665/177869/WHO_MERS_SUR_15.1_eng.pdf;sequence=1)


Acknowledgements

The following people contributed to the drafting of this guidance document: Maria Zambon, Public Health England, UK; Christian Drosten, Charité - Universitätsmedizin Berlin, Germany; Marion Koopmans, Erasmus MC, Rotterdam, The Netherlands; David Alland, Rutgers Medical School, USA; George Gao, Chinese CDC, China.

WHO Health Emergency Programme: Katelijn Vandemaele, Magdi Samaan, Christian Fuster, Wenqing Zhang, Céline Barnadas, Lisa Stevens, Chris Oxenford, Sebastian Cognat, Kazunobu Kojima, Carmen Dolea, Maria Van Kerkhove, Mark D Perkins and Karin von Eije. WHO Science Division: Vasee Moorthy

8. References


3) Investigation of cases of human infection with Middle East respiratory syndrome coronavirus (MERS-CoV), interim guidance, World Health Organization, updated June 2018 WHO/ERS/SUR/15.2 Revision 1 (https://apps.who.int/iris/bitstream/handle/10665/178252/WHO_MERS_SUR_15.2_eng.pdf;sequence=1)

4) Surveillance for human infection with Middle East respiratory syndrome coronavirus (MERS-CoV), interim guidance, Updated June 2018, WHO/MERS/SUR/15.1 Revision 1 (https://apps.who.int/iris/bitstream/handle/10665/177869/WHO_MERS_SUR_15.1_eng.pdf;sequence=1)

Laboratory testing for 2019 novel coronavirus (2019-nCOV) in suspected human cases


© World Health Organization 2020. All rights reserved.

This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.